Cochrane · systematic review · CD009310
Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes
Hutzschenreuter, F, Monsef, I, Kreuzer, KA, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
10
No studies
4
Included studies
NR
No studies 4 · 28.6%Ungraded 0 · 0%Very low 5 · 35.7%Low 5 · 35.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
G‐CSF compared to placebo for newly diagnosed patients with myelodysplastic syndromes
Population: newly diagnosed patients with myelodysplastic syndromes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival G‐CSF vs placebo | HR 0.8 [0.44, 1.46] | 1 study · 64 participants | Very low Downgraded: imprecision |
Progression‐free survival G‐CSF vs placebo | no estimate extracted | 1 study · 64 participants | Very low Downgraded: imprecision |
Time to progression to AML G‐CSF vs placebo | no estimate extracted | 2 studies · 111 participants | Very low Downgraded: imprecision |
Quality of life G‐CSF vs placebo | no estimate extracted | NR | No studies |
Infections G‐CSF vs placebo | no estimate extracted | 2 studies · 167 participants | Very low Downgraded: imprecision |
Severe adverse events G‐CSF vs placebo | no estimate extracted | NR | No studies |
Blood transfusions G‐CSF vs placebo | no estimate extracted | 1 study · 64 participants | Very low Downgraded: imprecision |
GM‐CSF compared to placebo for newly diagnosed patients with myelodysplastic syndromes
Population: newly diagnosed patients with myelodysplastic syndromes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (12 months GM‐CSF vs placebo | HR 0.88 [0.62, 1.26] | 2 studies · 149 participants | Low Downgraded: imprecision |
Progression‐free survival GM‐CSF vs placebo | no estimate extracted | 2 studies · 149 participants | Low Downgraded: imprecision |
Time to progression to AML GM‐CSF vs placebo | no estimate extracted | NR | No studies |
Quality of life GM‐CSF vs placebo | no estimate extracted | NR | No studies |
Infections GM‐CSF vs placebo | no estimate extracted | 1 study · 118 participants | Low Downgraded: imprecision |
Serious adverse events GM‐CSF vs placebo | no estimate extracted | 2 studies · 149 participants | Low Downgraded: imprecision |
Blood transfusions GM‐CSF vs placebo | no estimate extracted | 1 study · 31 participants | Low Downgraded: imprecision |